ALTIMMUNE INC (ALT) Stock Price, Forecast & Analysis
USA - NASDAQ:ALT - US02155H2004 - Common Stock
ALT Key Statistics, Chart & Performance
The current stock price of ALT is 3.76 USD. In the past month the price decreased by -4.33%. In the past year, price decreased by -51.04%.
ALT Latest News, Press Relases and Analysis
ALT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About ALT
Company Profile
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Company Info
ALTIMMUNE INC
910 Clopper Road, Suite 201S
Gaithersburg MARYLAND 20878 US
CEO: Vipin K. Garg
Employees: 59
Phone: 12406541450
ALTIMMUNE INC / ALT FAQ
What does ALTIMMUNE INC do?
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Can you provide the latest stock price for ALTIMMUNE INC?
The current stock price of ALT is 3.76 USD. The price decreased by -5.05% in the last trading session.
What is the dividend status of ALTIMMUNE INC?
ALT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALT stock?
ALT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for ALTIMMUNE INC?
The Revenue of ALTIMMUNE INC (ALT) is expected to grow by 37.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for ALT stock?
ALTIMMUNE INC (ALT) currently has 59 employees.
ALT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALT. When comparing the yearly performance of all stocks, ALT is a bad performer in the overall market: 86.98% of all stocks are doing better.
ALT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALT. While ALT seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALT Financial Highlights
Over the last trailing twelve months ALT reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 16.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.1% | ||
| ROE | -54.38% | ||
| Debt/Equity | 0.09 |
ALT Forecast & Estimates
14 analysts have analysed ALT and the average price target is 18.81 USD. This implies a price increase of 400.35% is expected in the next year compared to the current price of 3.76.
For the next year, analysts expect an EPS growth of 16.26% and a revenue growth 37.6% for ALT